Aquestive Therapeutics, Inc. Long-term Debt and Lease Obligation
Aquestive Therapeutics, Inc. (AQST) had Long-term Debt and Lease Obligation of $50.65 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation
us-gaap:LongTermDebtAndCapitalLeaseObligations · last filed 2026-08-11
- 2026-06-30: Long-term Debt and Lease Obligation $50.65M.
- 2026-03-31: Long-term Debt and Lease Obligation $25.10M.
- 2025-12-31: Long-term Debt and Lease Obligation $27.52M.
- 2024-12-31: Long-term Debt and Lease Obligation $32.50M.
| Period end | Long-term Debt and Lease Obligation |
|---|---|
| 2026-06-30 | $50.65M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $25.10M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $27.52M 10-Q · filed 2026-08-11 |
| 2024-12-31 | $32.50M 10-K · filed 2026-03-04 |
| 2023-12-31 | $27.51M 10-K · filed 2025-03-05 |
| 2022-12-31 | $33.45M 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |